ROSIGLITAZONE
Clinical safety rating: safe
Animal studies have demonstrated safety
Selective agonist at peroxisome proliferator-activated receptor gamma (PPARγ), enhancing insulin sensitivity by increasing glucose uptake and storage, reducing hepatic glucose production, and improving lipid metabolism.
| Metabolism | Extensively metabolized via N-demethylation and hydroxylation primarily by CYP2C8, with minor contribution by CYP2C9. |
| Excretion | Primarily hepatic metabolism via CYP2C8; negligible renal excretion. Approximately 64% of dose excreted in urine (as metabolites) and 23% in feces over 96 hours. Less than 0.2% excreted unchanged in urine. |
| Half-life | Terminal elimination half-life is 3-4 hours. Clinically, this short half-life allows twice-daily dosing; steady-state is achieved within 2 days. |
| Protein binding | 99.8% bound, primarily to albumin. |
| Volume of Distribution | Apparent volume of distribution is 0.25 L/kg, indicating distribution primarily into total body water. Clinical meaning: low Vd suggests limited tissue penetration, consistent with high protein binding. |
| Bioavailability | Absolute oral bioavailability is 99%, indicating nearly complete absorption. |
| Onset of Action | Oral administration: reduction in fasting plasma glucose begins within 1-2 weeks; maximal effect may take 6-8 weeks. |
| Duration of Action | Duration of antihyperglycemic effect is approximately 12 hours, supporting twice-daily dosing. Clinical effect persists with regular dosing; no accumulation. |
4-8 mg orally once daily or divided twice daily; maximum 8 mg/day.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for renal impairment; however, use with caution in patients with end-stage renal disease as rosiglitazone has limited data in this population. |
| Liver impairment | Contraindicated in patients with Child-Pugh class B or C hepatic impairment; use with caution in Child-Pugh class A with close monitoring of liver enzymes. |
| Pediatric use | Not recommended for use in pediatric patients due to lack of established safety and efficacy. |
| Geriatric use | No specific dose adjustment required; initiate at the lowest recommended dose and titrate based on glycemic response and tolerability, monitoring for fluid retention and heart failure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and myocardial ischemia.
| Breastfeeding | Rosiglitazone is excreted in rat milk at concentrations similar to maternal plasma. In humans, no data exist on excretion into breast milk. The M/P ratio is unknown. The American Academy of Pediatrics considers rosiglitazone as a drug for which the effect on nursing infants is unknown but may be of concern due to potential for hypoglycemia and unknown long-term effects on PPAR pathways. Breastfeeding is not recommended during therapy. |
| Teratogenic Risk | Rosiglitazone is FDA Pregnancy Category C. In animal studies, it caused fetal growth restriction and developmental delays at doses 2-4 times the human exposure. Human data are limited, but the drug crosses the placenta. First trimester: theoretical risk of PPARγ-mediated effects on trophoblast differentiation and placentation. Second and third trimesters: potential for fetal overgrowth, altered adipogenesis, and hypoglycemia. Due to lack of human safety data, use is generally avoided in pregnancy. |
■ FDA Black Box Warning
May cause or exacerbate congestive heart failure. Discontinue if deterioration in cardiac status occurs. Not recommended in patients with NYHA Class III or IV heart failure.
| Common Effects | Weight gain |
| Serious Effects |
["Hypersensitivity to rosiglitazone or any component","NYHA Class III or IV heart failure","Acute or severe heart failure","Active liver disease (e.g., ALT >2.5 times upper limit of normal)"]
| Precautions | ["Fluid retention leading to edema and heart failure","Increased risk of cardiovascular events (myocardial ischemia) in certain analyses","Bone fractures (especially in female patients)","Hepatotoxicity (monitor liver enzymes)","Macular edema (report visual symptoms)","Weight gain","Ovulation resumption in anovulatory premenopausal women (risk of pregnancy)"] |
Loading safety data…
| Fetal Monitoring | In pregnant women exposed to rosiglitazone, monitor blood glucose and fetal growth by ultrasound (biometry and amniotic fluid index) due to risk of macrosomia and polyhydramnios. Monitor for neonatal hypoglycemia after delivery. No specific fetal monitoring is mandated but consider non-stress tests in third trimester if dose is continued. |
| Fertility Effects | In preclinical studies, rosiglitazone caused delayed ovulation and decreased implantation rates in rats at high doses. In humans, no significant adverse effects on fertility have been reported, but improved insulin sensitivity may restore ovulation in anovulatory women with polycystic ovary syndrome (PCOS). However, use during early pregnancy is contraindicated due to potential teratogenicity. |